What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2022-08-03 compared with 2022-02-14 · 62 added, 38 removed, 6 unchanged (94% of the section changed)

Other Information.

The following exhibits are filed

as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

Description of Exhibit

Underwriting Agreement, dated October 26, 2021, by and between the Company and I-Bankers Securities, Inc., as representative of the several underwriters (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the Commission on November 1, 2021).

Business Combination Marketing Agreement, dated October 26, 2021, by and between the Company and I-Bankers Securities, Inc.

following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

Agreement, dated October 26, 2021, by and between the Company and I-Bankers Securities, Inc., as representative of the several underwriters

(incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the Commission on November

Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on November 1, 2021.)

Certificate of Correction to the Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on November 4, 2021).

Bylaws (incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form S-1 (File No.

333-259500) filed with the Commission on September 13, 2021).

Rights Agreement, dated October 26, 2021, by and between the Company and American Stock Transfer & Trust Company, LLC, as rights agent (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Commission on November 1, 2021).

Letter Agreement, dated October 26, 2021, by and among the Company, its officers, its directors, Bright Vision Sponsor LLC and I-Bankers Securities, Inc.

Combination Marketing Agreement, dated October 26, 2021, by and between the Company and I-Bankers Securities, Inc.

(incorporated

by reference to Exhibit 1.2 to the Company’s Current Report on Form 8-K filed with the Commission on November 1, 2021).

Combination Agreement dated July 12, 2022, among Deep Medicine Acquisition Corp., Chijet Inc., Chijet Motor Company, Inc., Chijet

Motor (USA) Company, Inc.

and the Sellers named therein (incorporated by reference to Exhibit 2.1 to the Company’s Current

Report on Form 8-K filed with the Commission on July 18, 2022).

of Correction to the Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s

Current Report on Form 8-K filed with the Commission on November 4, 2021).

(incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form S-1 (File No.

333-259500) filed with

the Commission on September 13, 2021).

Agreement, dated October 26, 2021, by and between the Company and American Stock Transfer & Trust Company, LLC, as rights agent

(incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Commission on November

Investment Management Trust Agreement, dated October 26, 2021, by and between the Company and American Stock Transfer & Trust Company, LLC, as trustee (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Commission on November 1, 2021).

Registration Rights Agreement, dated October 26, 2021, by and among the Company and certain security holders (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the Commission on November 1, 2021).

Private Placement Units Purchase Agreement, dated October 26, 2021, by and among the Company, Bright Vision Sponsor LLC and I-Bankers Securities, Inc.

Agreement, dated October 26, 2021, by and among the Company, its officers, its directors, Bright Vision Sponsor LLC and I-Bankers

Securities, Inc.

(incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission

on November 1, 2021).

Management Trust Agreement, dated October 26, 2021, by and between the Company and American Stock Transfer & Trust Company, LLC,

(incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Commission

on November 1, 2021).

Rights Agreement, dated October 26, 2021, by and among the Company and certain security holders.

(incorporated by reference to Exhibit

10.3 to the Company’s Current Report on Form 8-K filed with the Commission on November 1, 2021).

Placement Units Purchase Agreement, dated October 26, 2021, by and among the Company, Bright Vision Sponsor LLC and I-Bankers Securities,

(incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the Commission on November

Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Certification of Principal Executive Officer Pursuant to 18 U.S.C.

Agreement dated July 12, 2022, among Deep Medicine Acquisition Corp., Bright Vision Sponsor LLC, Chijet Inc.

and Chijet Motor Company,

(incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on July

of Lock-Up Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the

Commission on July 18, 2022).

of Amended and Restated Registration Rights Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Current Report

on Form 8-K filed with the Commission on July 18, 2022).

Certification

of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section

302 of the Sarbanes-Oxley Act of 2002

Certification

of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section

302 of the Sarbanes-Oxley Act of 2002

Certification

of Principal Executive Officer Pursuant to 18 U.S.C.

Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of

Certification of Principal Financial Officer Pursuant to 18 U.S.C.

Certification

of Principal Financial Officer Pursuant to 18 U.S.C.

Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of

Inline XBRL Instance Document

Inline XBRL Taxonomy Extension Schema Document

Inline XBRL Taxonomy Extension Calculation Linkbase

Inline XBRL Taxonomy Extension Definition Linkbase

Inline XBRL Taxonomy Extension Labels Linkbase Document

Inline XBRL Taxonomy Extension Presentation Linkbase

Cover Page Interactive Data File.

Filed herewith.

Furnished herewith.

In accordance with the requirements

of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly

DEEP MEDICINE ACQUISITION CORP.

February 14, 2022

/s/ Humphrey P.

Chief Executive Officer

(Principal Executive Officer)

February 14, 2022

/s/ Weixuan Luo

Chief Financial Officer

(Principal Financial and Accounting Officer)

XBRL Instance Document

XBRL Taxonomy Extension Schema Document

XBRL Taxonomy Extension Calculation Linkbase Document

XBRL Taxonomy Extension Definition Linkbase Document

XBRL Taxonomy Extension Labels Linkbase Document

XBRL Taxonomy Extension Presentation Linkbase Document

Page Interactive Data File.

of the exhibits, appendices, annexes and/or schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2).

The Registrant agrees to furnish supplementally a copy of all omitted exhibits, annexes, appendices and schedules to the Securities

and Exchange Commission upon its request.

accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf

by the undersigned, thereunto duly authorized.

MEDICINE ACQUISITION CORP.

August 3, 2022

Executive Officer

Executive Officer)

August 3, 2022

Financial Officer

Financial and Accounting Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information